Jeff Yass’s PharmaCyte Biotech PMCB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.3K Sell
1,582
-779
-33% -$8.14K ﹤0.01% 13205
2026
Q2
$34.5K Buy
+2,361
New +$33.8K ﹤0.01% 12930
2025
Q3
– Sell
-1,453
Closed -$30.4K – 13566
2025
Q2
$30.4K Buy
1,453
+484
+50% +$10.3K ﹤0.01% 12249
2025
Q1
$23K Sell
969
-846
-47% -$26.1K ﹤0.01% 12076
2024
Q4
$53.4K Sell
1,815
-39
-2% -$1.28K ﹤0.01% 11646
2024
Q3
$67.3K Sell
1,854
-1,032
-36% -$36.5K ﹤0.01% 11254
2024
Q2
$107K Buy
2,886
+718
+33% +$29.4K ﹤0.01% 10981
2024
Q1
$97.6K Buy
2,168
+1,009
+87% +$41.5K ﹤0.01% 11232
2023
Q4
$47.6K Buy
+1,159
New +$47.7K ﹤0.01% 11733
2023
Q2
– Sell
-5,626
Closed -$311K – 12889
2023
Q1
$311K Buy
+5,626
New +$314K ﹤0.01% 9646
2022
Q4
– Sell
-875
Closed -$47.6K – 13392
2022
Q3
$40K Sell
875
-3,262
-79% -$157K ﹤0.01% 12334
2022
Q2
$178K Buy
4,137
+2,660
+180% +$110K ﹤0.01% 10810
2022
Q1
$65K Buy
+1,477
New +$62.3K ﹤0.01% 12173

Other funds holding PMCB

Jeff Yass's PMCB Position: Q3 2026 in Review

Jeff Yass reduced its PharmaCyte Biotech (PMCB) stake by 33% in Q3 2026, selling an estimated $8.14K and leaving 1,582 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #13205.

Jeff Yass first reported a position in PMCB in Q1 2022 and has held it in 13 quarters since. The position peaked at $311K in Q1 2023. 20 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • Jeff Yass held 1,582 shares of PharmaCyte Biotech worth $12.3K as of Q3 2026.
  • Jeff Yass sold 779 PharmaCyte Biotech shares in Q3 2026, an estimated $8.14K.
  • PharmaCyte Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #13205 holding.
  • Jeff Yass first reported a position in PharmaCyte Biotech in Q1 2022 and has held it in 13 quarters since.
  • Jeff Yass's PharmaCyte Biotech position peaked at $311K in Q1 2023.
  • 20 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.